Quintrio
Home

PHARMACEUTICAL PREPARATIONS

ABBVIE INC.

ABBV

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.

Last trade $292.73
Day change -$1.82 (-0.62%)
Day range $290.81 – $296.22
Volume 1,690,047
Market cap $520.65B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$520.65B
Price / earnings
50.39×
Price / book
-113.6×
Price / sales
7.89×
EV / sales
8.95×
EV / EBITDA
18.94×

Profitability

Earnings per share
$5.85
Return on assets
7%
Return on equity
-225.44%
Dividend yield
2.33%

Liquidity and leverage

Debt / equity
-17.65×
Current ratio
0.87×
Quick ratio
0.75×
Cash ratio
0.25×

Cash flow

Price / cash flow
25.92×
Price / free cash flow
27.59×
Free cash flow
$18.87B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ABBV, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$17.4B$16.99B$15B$16.62B$15.78B$15.42B$13.34B$15.1B
Cost of revenue$4.29B$4.29B$4.22B$4.55B$5.3B$4.35B$4B$4.4B
Gross profit$13.12B$12.7B$10.78B$12.07B$10.47B$11.08B$9.34B$10.71B
Selling, general and administrative$4.09B$3.63B$3.58B$3.9B$3.57B$3.25B$3.29B$3.86B
Research and development$2.57B$2.34B$2.47B$2.58B$2.32B$2.13B$2.07B$6.77B
Total operating expenses$6.85B$6.27B$6.79B$7.74B$8.57B$6.18B$5.61B$12.2B
Operating income$6.27B$6.43B$3.99B$4.33B$1.9B$4.89B$3.73B-$1.5B
Interest expense-$700M-$679M$0$0-$667M-$678M$0$0
Income before taxes$4.83B$4.28B$1.04B$2.67B$714M$1.55B$1.66B-$2.27B
Income taxes$609M$662M$342M$853M$526M$613M$372M-$2.25B
Net income$4.22B$3.62B$697M$1.82B$188M$941M$1.29B-$23M
Net income attributable to common shareholders$4.22B$3.61B$695M$1.81B$186M$938M$1.29B-$32M
EBITDA$8.34B$8.61B$6.67B$7.58B$6.65B$7.77B$6.02B$2.18B
Basic earnings per share$2.38$2.04$0.39$1.02$0.10$0.52$0.72-$0.02
Diluted earnings per share$2.37$2.03$0.39$1.02$0.10$0.52$0.72-$0.02

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?

AstraZeneca reported Q3 2026 revenues of $16.21 billion (up 7% YoY) and core EPS of $2.79, beating consensus estimates. Strong oncology sales growth (16% to $21.9B) and new drug launches support the company's $80 billion 2030 revenue target. However, generic erosion of mature drugs, recent pipeline failures, and China market uncertainties create headwinds. The company maintains mid-to-high single-digit revenue growth guidance for 2026.

Zacks Investment Research

J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts

Johnson & Johnson announced a $2.2 billion acquisition of clinical-stage biotech Ollin Biosciences to expand its ophthalmology pipeline with OLN324, a phase III bispecific antibody for retinal diseases. Blackstone will fund $750 million of the phase III development. This acquisition is part of J&J's broader strategy of pursuing strategic M&A to strengthen its Innovative Medicine and MedTech businesses, following recent acquisitions of Firefly Bio, Intra-Cellular Therapies, Shockwave Medical, and Abiomed.

Zacks Investment Research

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

AbbVie (ABBV) is trending among investors with shares up 4.2% over the past month, outperforming the S&P 500's -3% decline. The pharmaceutical company shows strong earnings growth expectations of +39.7% for the current fiscal year and +14.7% for next year, with a consistent track record of beating consensus estimates. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term. The company is valued at par with its peers based on valuation metrics.

Zacks Investment Research

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

The Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed healthcare sector ETF with $4.08 billion in assets and a low 0.08% expense ratio. Year-to-date performance is up 21.32%, with top holdings including Eli Lilly, Johnson & Johnson, and Abbvie. The ETF carries a Zacks ETF Rank of 3 (Hold) and offers medium-risk diversified exposure to 348 healthcare companies.

GlobeNewswire Inc.

Commit Biologics announces final close of $60 million seed financing to advance complement-powered immune engagers toward the clinic

Commit Biologics completed a $60 million seed financing round led by Ackermans & van Haaren, with participation from AbbVie Ventures and M Ventures. The funds will support IND-enabling activities and clinical development of COM002, its first development candidate, a dual-targeting bispecific complement engager designed for cancer and autoimmune disease treatment.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $1.82 per share
Declared
Oct 29, 2026
Ex-dividend
Jan 15, 2027
Pay date
Feb 16, 2027
Ex-dividendAmount / sharePay dateType
Oct 15, 2026$1.73Nov 16, 2026recurring
Jul 15, 2026$1.73Aug 14, 2026recurring
Apr 15, 2026$1.73May 15, 2026recurring
Jan 16, 2026$1.73Feb 17, 2026recurring
Oct 15, 2025$1.64Nov 14, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.